Biden administration wants Medicare, Medicaid to cover anti-obesity medicines

Contributing sentiments towards policy:

57% : The Biden-led White House estimates that the coverage would expand access to 3.4 million Medicare enrollees and 4 million people with Medicaid.
52% : According to guidance provided by the Centers for Medicare and Medicaid Services, Food and Drug Administration-approved anti-obesity medications can be used for an additional medically accepted indication.
46% : The plan, which would have to be finalized by the Trump administration, would allow Medicare and Medicaid to cover anti-obesity medicines for people with obesity.
45% : Currently, Medicare and most state Medicaid programs only cover these drugs for people diagnosed with obesity or those who are obese or overweight and have cardiovascular disease.
32% : The Congressional Budget Office also notes that federal spending could even be higher if the drugs extend the life expectancy of Americans who would collect Social Security and Medicare later in life.RELATED STORY | Ozempic, Wegovy may be linked to increased risk of condition that causes blindness, new study showsEarlier this year, the Biden administration expanded coverage of Wegovy.

*Our bias meter rating uses data science including sentiment analysis, machine learning and our proprietary algorithm for determining biases in news articles. Bias scores are on a scale of -100% to 100% with higher negative scores being more liberal and higher positive scores being more conservative, and 0% being neutral. The rating is an independent analysis and is not affiliated nor sponsored by the news source or any other organization.